Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRNDO-02
- Development stage
- Preclinical
- Lead developer
- Sirius Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
SRNDO-02 is a preclinical small interfering RNA (siRNA) therapeutic candidate being developed by Sirius Therapeutics (also known as Sirius Natural) for the treatment of obesity. The program is part of a broader pipeline of RNA-based therapies that utilize the company's proprietary delivery platforms to target specific tissues, including the liver, adipose tissue, heart, kidneys, and the central nervous system (CNS). SRNDO-02 functions through the RNA interference (RNAi) pathway to silence a specific, undisclosed gene target involved in the regulation of metabolism and body weight. The candidate is currently in the Pre-Clinical/IND stage of development.
02
Targets
F11 (Coagulation Factor XI)
Beyond the preview
Go deeper on SRNDO-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRNDO-02.